Michael Browning
@michaelbrowni19
psychiatrist, utter laser
Pramipexole vs. quetiapine vs. amantadine in TRD. Interesting open label, short term RCT using a surprisingly low dose (I suspect that the reported dose of 37.5mg of pramipexole is a typo and it should be 0.375mg) sciencedirect.com/science/articl…
Systematic review and meta-analysis: Stopping antidepressants leads to slight symptom increases compared to placebo, but these symptoms are not clinically significant and do not include mood changes. ja.ma/4lNdBIu
1/ Just out in @NatureMedicine : we show the opioid system modulates ketamine’s effects in major depressive disorder, with naltrexone pre‑treatment reducing acute glutamatergic activity and acute antidepressant effects. nature.com/articles/s4159…
Can administrative real-world data substitute for RCTs and offer propensity matching to reduce bias? Results often fail to correspond & @LGHemkens et al study showed direction of effect differed in 31% & CI failed to include RCT estimate in 56% pubmed.ncbi.nlm.nih.gov/26858277/
Big late stage win for Takeda! Oveporexton (TAK-861) hits on all endpoints in narcolepsy for the first-in-class orexin receptor 2 selective agonist. Congrats to Andy Plump and the team at $TAK - perseverance and conviction on the MoA paid off takeda.com/newsroom/newsr…
“Basically, if you are still someone who treats the Davies and Read estimate of antidepressant withdrawal as valid—take the L and move on! The data from clinical trials just doesn’t back it up.”
Playing Whack-a-Mole With the Uncertainties of Antidepressant Withdrawal Complacency is the wrong conclusion of a new debated study psychiatrymargins.com/p/playing-whac…
Playing Whack-a-Mole With the Uncertainties of Antidepressant Withdrawal Complacency is the wrong conclusion of a new debated study psychiatrymargins.com/p/playing-whac…
🎊Recently, colleagues from across the @NIHRresearch Mental Health Translational Research Collaboration (MH-TRC) gathered for a celebration of progress and partnership in mental health research. ➡️ oxfordhealthbrc.nihr.ac.uk/nihr-mental-he…
In February, I saw @michaelbrowni19 present the results of PAX-D, a randomised controlled trial of pramipexole in treatment-resistant depression Like many in the audience, I was blown away by the results (link in bio)
📷 🧠💉 Shingrix (shingles vaccine) may reduce dementia risk—possibly thanks to its adjuvant, AS01. In a new study, we found GSK’s Arexvy (RSV vaccine, also with AS01) is linked to similar protection. AS01 could hold promise for dementia prevention. 📄 nature.com/articles/s4154…
Trump's Justice Department is writing to academic journals (this one is a journal about chest diseases) demanding they publish alternative scientific viewpoints and fight 'misinformation' instead of just doing good peer-reviewed medical science.
The Trump regime is now using US Attorneys to intimidate academic journals by sending them letters demanding they explain how they ensure ‘viewpoint diversity.’ Journal editors should be public about this and coordinate to refuse to comply with these fascist tactics.
Big shout out to the wonderful team, Ni Xu (co-first), Kate Saunders, John Geddes, and @michaelbrowni19! Read our open-access full article here: authors.elsevier.com/sd/article/S23… (4/4)
Excited to announce a postdoc position to use EEG+RL to identify specific mechanisms of different antidepressants within a large clinical trial tinyurl.com/4nuv6pvu. Come work with a super team acplab.org. @UCL @UCLPsychiatry @wellcometrust @UCLIoN @MPC_CompPsych